Seres Therapeutics Announces Appointment Of Wael Hashad As Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President.

In this newly created role, Hashad will be responsible for all activities related to the anticipated commercialization of the company's products in development, including SER-109, which is currently in a Phase 2 clinical study for recurring Clostridium difficile infection (CDI). He will report to Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres.

Read more on